Evaluation of serum protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry for the detection of prostate cancer: I. Assessment of platform reproducibility

Clinical Chemistry

Volumn 51, Issue 1, 2005, Pages 102-112

  Semmes, O John ^a   Feng, Ziding ^b   Adam, Bao Ling ^a   Banez, Lionel L ^c   Bigbee, William L ^d   Campos, David ^e   Cazares, Lisa H ^a   Chan, Daniel W ^f   Grizzle, William E ^g   Izbicka, Elzbieta ^e   Kagan, Jacob ^h   Malik, Gunjan ^a   McLerran, Dale ^b   Moul, Judd W ^c   Partin, Alan ^f   Prasanna, Premkala ^c   Rosenzweig, Jason ^f   Sokoll, Lori J ^f   Srivastava, Shiv ^c   Srivastava, Sudhir ^h   Thompson, Ian ⁱ   Welsh, Manda J ^d   White, Nicole ^f   Winget, Marcy ^b   Yasui, Yutaka ^b   Zhang, Zhen ^f   Zhu, Liu ^g   more..

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^d UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^e CTRC Institute for Drug Development   (United States)

^f DEPARTMENT OF PATHOLOGY   (United States)

^g University of Alabama at Birmingham   (United States)

^h NATIONAL CANCER INSTITUTE   (United States)

ⁱ UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLASMA PROTEIN;

ARTICLE; CANCER SURVIVAL; CRYPTORCHISM; DIAGNOSTIC ACCURACY; EARLY DIAGNOSIS; EVALUATION; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; MASS SPECTROMETRY; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REPRODUCIBILITY; RISK ASSESSMENT; SCREENING; SURFACE ENHANCED LASER DESOPRTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY;

CALIBRATION; HUMANS; LABORATORIES; LABORATORY TECHNIQUES AND PROCEDURES; MALE; PROSTATIC NEOPLASMS; PROTEIN ARRAY ANALYSIS; PROTEOME; PROTEOMICS; QUALITY CONTROL; REPRODUCIBILITY OF RESULTS; SERUM; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 19944419092     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2004.038950     Document Type: Article

References (39)

1. Etzioni R, Urban N, Ramsey S, McIntosh M, Schwartz S, Reid B, et al. The case for early detection. Nat Rev Cancer 2003;3:243-52.
2. Gloeckler-Ries LA, Reichman ME, Lewis DR, Hankey BF, Edwards BK. Cancer survival and incidence from the Surveillance, Epidemiology, and End Results (SEER) program. Oncologist 2003;8:541-52.
3. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, et al. Cancer statistics, 2004. CA Cancer J Clin 2004;54:8-29.
4. Tiwari RC, Ghosh K, Jemal A, Hachey M, Ward E, Thun MJ, et al. A new method of predicting US and state-level cancer mortality counts for the current calendar year. CA Cancer J Clin 2004;54: 30-40.
5. Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM, et al. Use of proteomic patterns in serum to identify ovarian cancer 2002;359:572-7.
6. Adam BL, Qu Y, Davis JW, Ward MD, Clements MA, Cazares LH, et al. Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res 2002;62:3609-14.
7. Vlahou A, Laronga C, Wilson L, Gregory B, Fournier K, McGaughey D, et al. A novel approach toward development of a rapid blood test for breast cancer. Clin Breast Cancer 2003;4:203-9.
8. Qu Y, Adam BL, Yasui Y, Ward MD, Cazares LH, Schellhammer PF, et al. Boosted decision tree analysis of surface-enhanced laser desorption/ionization mass spectral serum profiles discriminates prostate cancer from noncancer patients. Clin Chem 2002;48: 1835-43.
9. Banez LL, Prasanna P, Sun L, Ali A, Zou Z, Adam BL, et al. Diagnostic potential of serum proteomic patterns in prostate cancer. J Urol 2003;170:442-6.
10. Cazares LH, Adam BL, Ward MD, Nasim S, Schellbammer PF, Semmes OJ, et al. Normal, benign, preneoplastic, and malignant prostate cells have distinct protein expression profiles resolved by surface enhanced laser desorption/ionization mass spectrometry. Clin Cancer Res 2002;8:2541-52.
11. Koopmann J, Zhang Z, White N, Rosenzweig J, Fedarko N, Jagannath S, et al. Serum diagnosis of pancreatic adenocarcinoma using surface-enhanced laser desorption and ionization mass spectrometry. Clin Cancer Res 2004;10:860-8.
12. Kozak KR, Amneus MW, Pusey SM, Su F, Luong MN, Luong SA, et al. Identification of biomarkers for ovarian cancer using strong anion-exchange. ProteinChips: potential use in diagnosis and prognosis. Proc Natl Acad Sci U S A 2003;100:12343-8.
13. Li J, Zhang Z, Rosenzweig J, Wang YY, Chan DW. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem 2002;48:1296-304.
14. Paweletz CP, Trock B, Pennanen M, Tsangaris T, Magnant C, Liotta LA, et al. Proteomic patterns of nipple aspirate fluids obtained by SELDI-TOF: potential for new biomarkers to aid in the diagnosis of breast cancer. Dis Markers 2001;17:301-7.
15. Petricoin EF 3rd, Ornstein DK, Paweletz CP, Ardekani A, Hackett PS, Hitt BA, et al. Serum proteomic patterns for detection of prostate cancer. J Natl Cancer Inst 2002;94:1576-8.
16. Poon TC, Yip TT, Chan AT, Yip C, Yip V, Mok TS, et al. Comprehensive proteomic profiling identifies serum proteomic signatures for detection of hepatocellular carcinoma and its subtypes. Clin Chem 2003;49:752-60.
17. Rosty C, Christa L, Kuzdzal S, Baldwin WM, Zahurak ML, Carnot F, et al. Identification of hepatocarcinoma-intestine-pancreas/pancreatitis-associated protein I as a biomarker for pancreatic ductal adenocarcinoma by protein biochip technology. Cancer Res 2002; 62:1868-75.
18. Vlahou A, Schellhammer PF, Mendrinos S, Patel K, Kondylis FI, Gong L, et al. Development of a novel proteomic approach for the detection of transitional cell carcinoma of the bladder in urine. Am J Pathol 2001;158:1491-502.
19. Wadsworth JT, Somers KD, Cazares LH, Malik G, Adam BL, Stack BC Jr, et al. Serum protein profiles to identify head and neck cancer. Clin Cancer Res 2004;10:1625-32.
20. Wadsworth JT, Somers KD, Stack BC Jr, Cazares L, Malik G, Adam BL, et al. Identification of patients with head and neck cancer using serum protein profiles. Arch Otolaryngol Head Neck Surg 2004;130:98-104.
21. Won Y, Song HJ, Kang TW, Kim JJ, Han BD, Lee SW. Pattern analysis of serum proteome distinguishes renal cell carcinoma from other urologic diseases and healthy persons. Proteomics 2003;3:2310-6.
22. Wulfkuhle JD, McLean KC, Paweletz CP, Sgroi DC, Trock BJ, Steeg PS, et al. New approaches to proteomic analysis of breast cancer. Proteomics 2001;1:1205-15.
23. Xiao X, Liu D, Tang Y, Guo F, Xia L, Liu J, et al. Development of proteomic patterns for detecting lung cancer. Dis Markers 2003; 19:33-9.
24. Zhukov TA, Johanson RA, Cantor AB, Clark RA, Tockman MS. Discovery of distinct protein profiles specific for lung tumors and pre-malignant lung lesions by SELDI mass spectrometry. Lung Cancer 2003;40:267-79.
25. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level, < or = 4.0 ng per milliliter. N Engl J Med 2004;22:2239-46.
26. Check E. Proteomics and cancer: running before we can walk? Nature 2004;429:496-7.
27. Diamandis EP. Analysis of serum proteomic patterns for early cancer diagnosis: drawing attention to potential problems. J Natl Cancer Inst 2004;96:353-6.
28. Diamandis EP. Re: diagnostic potential of serum proteomic patterns in prostate cancer. J Urol 2004;171:1244-5 [author reply 124-5-64].
29. Sorace JM, Zhan M. A data review and re-assessment of ovarian cancer serum proteomic profiling. BMC Bioinformatics 2003;4: 24.
30. Baggerly KA, Morris JS, Coombes KR. Reproducibility of SELDI-TOF protein patterns in serum: comparing datasets from different experiments. Bioinformatics 2004;20:777-85.
31. Gao CL, Rawal SK, Sun L, Ali A, Connelly RR, Banez LL, et al. Diagnostic potential of prostate-specific antigen expressing epithelial cells in blood of prostate cancer patients. Clin Cancer Res 2003;9:2545-50.
32. Grizzle WE, Adam BL, Bigbee WL, Conrads TP, Carroll C, Feng Z, et al. Serum protein expression profiling for cancer detection: validation of a SELDI-based approach for prostate cancer. Dis Markers 2003;19:185-95.
33. Yasui Y, Pepe M, Thompson ML, Adam BL, Wright GL Jr, Qu Y, et al. A data-analytic strategy for protein biomarker discovery: profiling of high-dimensional proteomic data for cancer detection. Biostatistics 2003;4:449-63.
34. Yasui Y, McLerran D, Adam BL, Winget M, Thomquist M, Feng Z. An automated peak-identification/calibration procedure for high-dimensional protein measures from mass spectrometers. J Biomed Biotechnol 2003;2003:242-8.
35. Sullivan Pepe M, Etzioni R, Feng Z, Potter JD, Thompson ML, Thomquist M, et al. Phases of biomarker development for early detection of cancer [Review]. J Natl Cancer Inst 2001;93:1054-61.
36. Ransohoff DF. Rules of evidence for cancer molecular-marker discovery and validation. Nat Rev Cancer 2004;4:309-14.
37. Grizzle WE, Semmes OJ, Basler J, Izbicka E, Feng Z, Kagan J, et al. The early detection research network surface-enhanced laser desorption and ionization prostate cancer detection study: a study in biomarker validation in genitourinary oncology. Urol Oncol 2004;22:337-43.
38. Grizzle WE, Meleth S. Clarification in the Point/Counterpoint discussion related to surface-enhanced laser desorption/ionization time-of-flight mass spectrometric identification of patients with adenocarcinomas of the prostate [Letter]. Clin Chem 2004; 50:1475-6.
39. Petricoin EF. Liotta LA. Proteomic pattern complexity reveals a rich and uncharted continent of biomarkers [Reply]. Clin Chem 2004; 50:1476-7.